André Renaldo Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
André Renaldo Fernández has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Marcos López-Hoyos
Department of Molecular Biology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Immunopathology Group, University of Cantabria, Santander, Spain
2 shared publications - David San Segundo
Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain
1 shared publication - Jordi Ochando
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication - María Gutiérrez-Larrañaga
Department of Immunology, Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), 39008 Santander, Spain
1 shared publication - Paolo Cravedi
Translational Transplant Research Center (TTRC), Department of Medicine, Renal Division, Icahn School of Medicine at Mount Sinai, New York, NY
1 shared publication - Rodrigo Sánchez-Tarjuelo
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 13 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (22) , 8549
Review: Ischemia Reperfusion Injury—A Translational Perspective in Organ Transplantation
Thanks to the development of new, more potent and selective immunosuppressive drugs together with advances in surgical techniques, organ transplantation has emerged from an experimental surgery over fifty years ago to being the treatment of choice for many end-stage organ diseases, with over 139,000 organ transplants performed worldwide in 2019. Inherent to the transplantation procedure is the fact that the donor organ is subjected to blood flow cessation and ischemia during harvesting, which is followed by preservation and reperfusion of the organ once transplanted into the recipient. Consequently, ischemia/reperfusion induces a significant injury to the graft with activation of the immune response in the recipient and deleterious effect on the graft. The purpose of this review is to discuss and shed new light on the pathways involved in ischemia/reperfusion injury (IRI) that act at different stages during the donation process, surgery, and immediate post-transplant period. Here, we present strategies that combine various treatments targeted at different mechanistic pathways during several time points to prevent graft loss secondary to the inflammation caused by IRI.
- 13 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (22) , 8549
Top Cited PapersOpen AccessReview: Ischemia Reperfusion Injury—A Translational Perspective in Organ Transplantation
Thanks to the development of new, more potent and selective immunosuppressive drugs together with advances in surgical techniques, organ transplantation has emerged from an experimental surgery over fifty years ago to being the treatment of choice for many end-stage organ diseases, with over 139,000 organ transplants performed worldwide in 2019. Inherent to the transplantation procedure is the fact that the donor organ is subjected to blood flow cessation and ischemia during harvesting, which is followed by preservation and reperfusion of the organ once transplanted into the recipient. Consequently, ischemia/reperfusion induces a significant injury to the graft with activation of the immune response in the recipient and deleterious effect on the graft. The purpose of this review is to discuss and shed new light on the pathways involved in ischemia/reperfusion injury (IRI) that act at different stages during the donation process, surgery, and immediate post-transplant period. Here, we present strategies that combine various treatments targeted at different mechanistic pathways during several time points to prevent graft loss secondary to the inflammation caused by IRI.
- Open Access
- 15 July 2020
- Published by MDPI AG in Transplantology
- Vol. 1 (1) , 24-41
Non-HLA Abs in Solid Organ Transplantation
The role of anti-HLA antibodies in solid organ rejection is well established and these antibodies are routinely monitored both in patients in the waiting list and in the post-transplant setting. More recently, the presence of other antibodies directed towards non-HLA antigens, or the so-called minor histocompatibility antigens, has drawn the attention of the transplant community; however, their possible involvement in the graft outcome remains uncertain. These antibodies have been described to possibly have a role in rejection and allograft failure. This review focuses on the most studied non-HLA antibodies and their association with different clinical outcomes considered in solid organ transplantation with the aim of clarifying their clinical implication and potential relevance for routine testing.
- 15 July 2020
- Published by MDPI AG in Transplantology
- Vol. 1 (1) , 24-41
Open AccessNon-HLA Abs in Solid Organ Transplantation
The role of anti-HLA antibodies in solid organ rejection is well established and these antibodies are routinely monitored both in patients in the waiting list and in the post-transplant setting. More recently, the presence of other antibodies directed towards non-HLA antigens, or the so-called minor histocompatibility antigens, has drawn the attention of the transplant community; however, their possible involvement in the graft outcome remains uncertain. These antibodies have been described to possibly have a role in rejection and allograft failure. This review focuses on the most studied non-HLA antibodies and their association with different clinical outcomes considered in solid organ transplantation with the aim of clarifying their clinical implication and potential relevance for routine testing.